SHARE-BASED COMPENSATION (Tables)
|
12 Months Ended |
Jul. 31, 2025 |
|---|
| Defined Benefit Plan Disclosure [Line Items] |
|
| SUMMARY OF NUMBER OF OPTIONS GRANTED |
SUMMARY OF NUMBER OF OPTIONS GRANTED
| | |
Number
of options | | |
Weighted
average exercise
price (*) | | |
Weighted
average remaining contractual term (in
years) | | |
Aggregate intrinsic
value | |
| | |
| | |
| | |
| | |
| |
| Balance as of July 31, 2023 and 2024 | |
| 14,183 | | |
$ | 923.53 | | |
| 2.52 | | |
$ | - | |
| Granted (i) | |
| 333 | | |
| 60.00 | | |
| 4.45 | | |
| - | |
| Forfeited | |
| (1,265 | ) | |
| 978.16 | | |
| | | |
| | |
| Balance as of July 31, 2025 | |
| 13,251 | | |
| 896.61 | | |
| 1.62 | | |
| - | |
| | |
| | | |
| | | |
| | | |
| | |
| Exercisable as of July 31, 2024 | |
| 13,152 | | |
$ | 924.60 | | |
| 2.41 | | |
$ | - | |
| Exercisable as of July 31, 2025 | |
| 13,251 | | |
$ | 896.61 | | |
| 1.62 | | |
$ | - | |
| |
(i) |
On
January 16, 2025, the Company granted 333 stock options to a consultant at an exercise price of $60.00 per share. All options vested
in full on April 16, 2025. The options expire on January 16, 2030. The grant-date fair value of the award was $16,242. |
| |
|
|
| |
(ii) |
The
weighted-average grant date per-share fair value of stock options granted during 2025 and 2024 was $48.77 and $ nil respectively.
As of July 31, 2025, there are $nil of total unrecognized costs related to share-based compensation, as all costs have been fully
recognized. |
| |
|
|
| |
(*) |
certain
options are exercisable in Canadian dollars and translated to US Dollars at year end. |
|
| SCHEDULE OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS |
SCHEDULE
OF FAIR VALUE MEASUREMENT OF EQUITY - SETTLED SHARE OPTIONS
| | |
Year
ended July 31, | |
| | |
2025 | | |
2024(*) | |
| | |
| | |
| |
| Dividend yield | |
| 0.00 | % | |
| n/a | |
| Expected volatility of the share prices | |
| 112 | % | |
| n/a | |
| Risk-free interest rate | |
| 4.45 | % | |
| n/a | |
| Expected term (in years) | |
| 5.0 | | |
| n/a | |
| (*) |
There
were no options grants during the year end July 31, 2024. |
|
| SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS |
SCHEDULE
OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise price | | |
Options outstanding as
of July
31, 2025 | | |
Weighted average remaining contractual
term (years) | | |
Options exercisable
as of July
31, 2025 | | |
Weighted average remaining contractual term
(years) | | |
Expiry
Date |
| $ | 60.00 | | |
| 333 | | |
| 4.45 | | |
| 333 | | |
| 4.45 | | |
January 16, 2030 |
| $ | 904.50 | | |
| 2,663 | | |
| 2.89 | | |
| 2,663 | | |
| 2.89 | | |
June 20, 2028 |
| $ | 1,074.00 | | |
| 136 | | |
| 2.58 | | |
| 136 | | |
| 2.58 | | |
February 27, 2028 |
| $ | 907.97 | | |
| 1,195 | | |
| 2.01 | | |
| 1,195 | | |
| 2.01 | | |
August 02, 2027 |
| $ | 706.50 | | |
| 206 | | |
| 1.81 | | |
| 206 | | |
| 1.81 | | |
May 20, 2027 |
| $ | 1,126.50 | | |
| 1,000 | | |
| 1.54 | | |
| 1,000 | | |
| 1.54 | | |
February 16, 2027 |
| $ | 1,270.50 | | |
| 3,160 | | |
| 1.45 | | |
| 3,160 | | |
| 1.45 | | |
January 13, 2027 |
| $ | 1,074.83 | | |
| 81 | | |
| 1.25 | | |
| 81 | | |
| 1.25 | | |
November 01, 2026 |
| $ | 636.00 | | |
| 400 | | |
| 0.72 | | |
| 400 | | |
| 0.72 | | |
April 19, 2026 |
| $ | 636.00 | | |
| 4,077 | | |
| 0.66 | | |
| 4,077 | | |
| 0.66 | | |
March 29, 2026 |
| | | | |
| 13,251 | | |
| | | |
| 13,251 | | |
| | | |
|
|
| SCHEDULE OF RESTRICTED STOCK UNITS GRANTED |
The
following table summarizes the number of RSU’s granted to directors under the Omnibus Plan for year ended July 31, 2025:
SCHEDULE OF RESTRICTED STOCK UNITS GRANTED
| | |
Number of | | |
| |
| | |
RSU’s | | |
Aggregate | |
| | |
outstanding | | |
intrinsic
value | |
| Balance,
July 31, 2024 | |
| 128 | | |
$ | 14,400 | |
| Granted (i) | |
| 6,166 | | |
| 370,000 | |
| Exercised(ii) | |
| (6,294 | ) | |
| (384,000 | ) |
| Balance,
July 31, 2025 | |
| - | | |
$ | - | |
| |
(i) |
On
January 16, 2025, the Company granted RSU’s to the Chief Executive Officer (“CEO”)
as compensation for deferred salary, with immediate vesting. The fair value of these RSUs
was $, offsetting previously accrued compensation owed to the CEO.
Additionally,
on the same date, the Company granted
RSUs to a consultant, which fully vested on April 16, 2025. The fair value of these RSUs was $. |
| |
(ii) |
All
RSUs outstanding were exercised on July 13, 2025. As a result, no RSUs remained outstanding as of July 31, 2025. |
|
| SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES |
f.
The total share-based compensation expense related to all of the Company’s equity-based awards, recognized for the years ended
July 31, 2025 and 2024 is comprised as follows:
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSES
| | |
Year
ended July 31, | |
| | |
2025 | | |
2024 | |
| | |
| |
| Research and development expenses | |
$ | 120,050 | | |
$ | 734,986 | |
| General and administrative
expenses | |
| 656,829 | | |
| 1,069,092 | |
| Total
share-based compensation | |
$ | 776,879 | | |
$ | 1,804,078 | |
|
| Bria Pro Therapeutics Corp [Member] |
|
| Defined Benefit Plan Disclosure [Line Items] |
|
| SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS |
SCHEDULE OF OUTSTANDING AND EXERCISABLE OPTIONS
Exercise Price | | |
Options outstanding
as of
July 31, 2025 | | |
Options exercisable
as of
July 31, 2025 | | |
Expiry
Date |
| | | |
| | |
| | |
|
| $ | 0.0933 | | |
| 440,000 | | |
| 440,000 | | |
June 20, 2028 |
| $ | 0.1108 | | |
| 21,000 | | |
| 21,000 | | |
February 27, 2028 |
| $ | 0.0984 | | |
| 180,100 | | |
| 180,100 | | |
August 02, 2027 |
| $ | 0.0729 | | |
| 31,000 | | |
| 31,000 | | |
May 20, 2027 |
| $ | 0.1162 | | |
| 150,000 | | |
| 150,000 | | |
February 16, 2027 |
| $ | 0.1310 | | |
| 524,700 | | |
| 524,700 | | |
January 13, 2027 |
| $ | 0.1165 | | |
| 12,600 | | |
| 12,600 | | |
November 01, 2026 |
| $ | 0.0888 | | |
| 100,000 | | |
| 100,000 | | |
September 01, 2026 |
| $ | 0.0656 | | |
| 60,000 | | |
| 60,000 | | |
April 19, 2026 |
| $ | 0.0656 | | |
| 612,000 | | |
| 612,000 | | |
March 29, 2026 |
| | | | |
| 2,131,400 | | |
| 2,131,400 | | |
|
|